We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Announces the Appointment of Dr Liz Holmes as Chief Medical Officer Newly established role at further strengthens leadership team and supports global growth Dr Liz Holmes’ rare disease and oncology ...

GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax ... That rise came despite the approval of Merck & Co's 15-valent Vaxneuvance in July 2021, which has ...

Perlmutter, president, Merck Research Laboratories ... the concentrated biotech cluster of Boston and Cambridge biotech in Massachusetts, is the main model for this new approach.

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

The agreement grants Merck the option to license Evaxion’s preclinical vaccine candidates EVX-B2 and EVX-B3. Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 ...